Last reviewed · How we verify
TEW-7197
At a glance
| Generic name | TEW-7197 |
|---|---|
| Also known as | TEW-7197, FOLFOX, Vactosertib, vactosetib, vactosertib, EW-7197 |
| Sponsor | Joon Oh Park |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer (PHASE1)
- Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients (PHASE2)
- Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC (PHASE1, PHASE2)
- Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma (PHASE1, PHASE2)
- Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer (PHASE1, PHASE2)
- Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition (PHASE2)
- TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer (PHASE1, PHASE2)
- Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEW-7197 CI brief — competitive landscape report
- TEW-7197 updates RSS · CI watch RSS
- Joon Oh Park portfolio CI